Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study

Trial Profile

Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Daratumumab (Primary) ; Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 28 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top